Study: NCT02676466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil (Fish oil Placebo)
Description: The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.

Intervention type: OTHER
Group type: OTHER
Intervention: Corn Oil (Fish oil Placebo)
Description: The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.

Intervention type: OTHER
Group type: OTHER
Intervention: Corn Oil (Fish oil Placebo)
Description: The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.